Sydney Oesch 10/29/24 Sydney Oesch 10/29/24

Cervix Part 2

This is the second of three episodes covering cervical cancer. In this episode, we define locally advanced, metastatic, and recurrent cervical cancer. We will discuss the standard treatment options, including chemotherapy and immunotherapy choices.

Sydney Oesch 10/15/24 Sydney Oesch 10/15/24

Cervix Part 1

This is the first of three episodes covering cervical cancer. In this episode, we discuss the epidemiology, risk factors, and staging of cervical cancer. In addition, we review the role of surgical management in early stage cervical cancer.

Sydney Oesch 10/1/24 Sydney Oesch 10/1/24

Chemotherapy: HIPEC and IPC

In this episode, we discuss Intraperitoneal chemotherapy (IPC) and Heated Intraperitoneal Chemotherapy (HIPEC), including clinical trials of these agents in ovarian cancer and practical tips for utilizing HIPEC in clinical practice.

Sydney Oesch 9/17/24 Sydney Oesch 9/17/24

Chemotherapy: PARP-I, Bevacizumab, and Ovarian Cytotoxics

Chemotherapy: PARP-I, Bev, Ovarian Cytotoxics

In this episode, we discuss antineoplastic agents for ovarian cancer. We discuss PARP-inhibitors, homologous recombination deficiency, bevacizumab, as well as new cytotoxic chemotherapy used in the treatment of ovarian cancers.

Sydney Oesch 9/3/24 Sydney Oesch 9/3/24

Ovary Part 7

In part 7 of our ovarian cancer series, we discuss surgical considerations in ovarian cancer, including patient and disease-specific factors that can influence surgical decision making, methods to predict optimal cytoreduction, and the utility of secondary cytoreduction.

Sydney Oesch 8/20/24 Sydney Oesch 8/20/24

Ovary Part 6

In part 6 of our ovarian cancer series, we discuss germ cell tumors and sex cord stromal tumors, including surgical decision-making and adjuvant treatment recommendations.

Sydney Oesch 8/6/24 Sydney Oesch 8/6/24

Ovary Part 5

In this episode, we will discuss the nuances of workup and management of less common epithelial ovarian cancers, including clear cell, endometrioid, mucinous, and low grade serous carcinomas, borderline tumors, and carcinosarcomas.

Sydney Oesch 7/23/24 Sydney Oesch 7/23/24

Ovary Part 4

This is the fourth of seven episodes covering ovarian cancer. In this episode, we discuss the management of recurrent, platinum-resistant epithelial ovarian cancer. Join us to explore the prognosis of PROC, recommendations for systemic chemotherapy, the role of bevacizumab, the updates to FDA approval for PARPi use, and options for targeted therapies.

Sydney Oesch 7/9/24 Sydney Oesch 7/9/24

Ovary Part 3

This is the third of seven episodes covering ovarian cancer. In this episode, we discuss the management of recurrent, platinum-sensitive epithelial ovarian cancer. Join us to learn how to detect recurrence, preferred systemic therapy regimens, and the use of targeted agents.

Sydney Oesch 6/25/24 Sydney Oesch 6/25/24

Ovary Part 2

This is the second of seven episodes covering ovarian cancer. In this episode, we discuss the management of advanced stage epithelial ovarian cancer. Join us to learn about the importance of optimal debulking, options for up-front treatment, the utility of bevacizumab, and the use of PARP inhibitors.